Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

S. Healey, Jeff; D. Lópes, Renato; B. Granger, Christopher; Alings, Marco; Rivard, Léna; F. McIntyre, William; Atar, Dan; H. Birnie, David; Boriani, Giuseppe; John Camm, A.; Conen, David; W. Erath, Julia; R. Gold, Michael; H. Hohnloser, Stefan; Ip, John; Kautzner, Josef; Kutyifa, Valentina; Linde, Cecilia; Mabo, Philippe; H. Mairesse, Georges; Benezet Mazuecos, Juan; Cosedis Nielsen, Jens; Philippon, François; Proietti, Marco; Sticherling, Christian; Wong, Jorge; J. Wright, David; Zarraga, Ignatius; B. Coutts, Shelagh; J. Kaplan, Andrew; Pombo, Marta; Ayala-Paredes, Félix; Xu, Lizhen; Simek, K; Nevills, Sandra; Mian, Rajibul; J. Connolly, Stuart

doi:10.1056/nejmoa2310234

Public

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Published in New England Journal of Medicine • Nov 12, 2023

Authors:

Jeff S. Healey

Renato D. Lópes

Christopher B. Granger

Abstract

BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment w...

Subject

Atrial fibrillation

Apixaban

Subclinical infection

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!